Active	Status	Sponsor type	Region	Phase	Filter
7 Active 17 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DelBello, Melissa P
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)	Active, not recruiting	4	288	Europe, US	Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo	Shire, Takeda Development Center Americas, Inc.	Attention Deficit Hyperactivity Disorder	06/27	06/27
NCT01908192 / 2017-001168-39: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®	Terminated	2/3	60	US, RoW	NaBen®, Placebo	SyneuRx International (Taiwan) Corp	Schizophrenia	10/23	10/23
McNamara, Robert
No trials found
McLaughlin, Laura
No trials found
Fleischer, Leah
No trials found